Canda-based radiopharmaceuticals provider AtomVie Global Radiopharma has partnered with Australia-based Radiopharm Ventures (RV) to develop and manufacture 177Lu-BetaBart.
Radiopharm is a joint venture between Radiopharm Theranostics (RAD) and MD Anderson Cancer Center (MDACC) that provides radiopharmaceutical products.
The collaboration will combine RAD’s advanced platform of radiotherapeutic products and AtomVie’s radiopharmaceuticals manufactured and distributed worldwide.
177Lu-BetaBart is a monoclonal antibody developed by RAD and RV as part of a portfolio of their differentiated technologies.
It is a 177Lutetium-conjugated radio-antibody that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumour types.
Radiopharm managing director and CEO Riccardo Canevari said: “Our collaboration with AtomVie is a significant step forward in our mission to bring innovative radiopharmaceutical therapies to patients.
“Their proven track record in manufacturing and global distribution assures us that we are in capable hands as we progress through the clinical stages and prepare for potential commercialisation.”
According to AtomVie, 177Lu-BetaBart is the first potential targeted radiopharmaceutical against the 4Ig subtype of B7-H3, the most common subtype expressed in human tumours.
It has been specifically engineered with a shorter blood circulation time and reduced affinity for on-target off-tissue toxicity, to make it highly promising for human use in clinical settings.
Also, a Phase 1/2 first-in-human therapeutic study of 177Lu-BetaBart in multiple tumour types in the US is expected in mid-2025.
AtomVie will leverage its expertise in clinical development, including technology transfer, process and method development, clinical supply, and global distribution.
AtomVie CEO Bruno Paquin said: “We are thrilled to partner with RAD on such an important project. With our expertise in radiopharmaceutical manufacturing, we are confident that we can support RAD in advancing their innovative pipeline.
“This partnership reinforces our commitment to transforming patients’ lives with high-quality radiopharmaceuticals, as we continue to expand our capabilities in our new facility and empower novel radiotherapeutics to market.”
